Using DNA as a drug - bioprocessing and delivery strategies

DNA may take a leading role in a future generation of blockbuster therapeutics. DNA has inherent advantages over other biomolecules such as protein, RNA and virus-like particles including safety, production simplicity and higher stability at ambient temperatures. Vaccination is the principal measure for preventing influenza and reducing the impact of pandemics; however, vaccines take up to 8-9 months to produce, and the global production capacity is woefully low. With production times as short as 2 weeks, improved safety and stability, bioprocess engineering developments, and the ability to perform numerous therapeutic roles, DNA has the potential to meet the demands of emerging and existing diseases. DNA is experiencing sharp growths in demand as indicated by its use in gene therapy trials and DNA vaccine related patents. Of particular interest for therapeutic use is plasmid DNA (pDNA), a form of non-genomic DNA that makes use of cellular machinery to express proteins or antigens. The production stages of fermentation and downstream purification are considered in this article. Forward looking approaches to purifying and delivering DNA are reported, including affinity chromatography and nasal inhalation. The place that pDNA may take in the preparation for and protection against pandemics is considered. If DNA therapeutics and vaccines prove to be effective, the ultimate scale of production will be huge which shall require associated bioprocess engineering research and development for purification of this large, unique biomolecule.

[1]  S Somavarapu,et al.  Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. , 2005, Advanced drug delivery reviews.

[2]  Olivier Denis,et al.  Improved Immunogenicity and Protective Efficacy of a Tuberculosis DNA Vaccine Encoding Ag85 by Protein Boosting , 2001, Infection and Immunity.

[3]  Magda Marquet,et al.  Process development for the manufacture of plasmid DNA vectors for use in gene therapy , 1996 .

[4]  J. Biewenga,et al.  The role of nasopharyngeal lymphoid tissue. , 1992, Immunology today.

[5]  D. Kaslow,et al.  A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases. , 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[6]  D. Riesenberg,et al.  High-cell-density cultivation of Escherichia coli. , 1991, Current opinion in biotechnology.

[7]  Huanting Wang,et al.  Process considerations related to the microencapsulation of plasmid DNA via ultrasonic atomization , 2008, Biotechnology and bioengineering.

[8]  M. Marquet,et al.  High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. , 1996, Human gene therapy.

[9]  M. A. Liu,et al.  DNA vaccines: a review , 2003, Journal of internal medicine.

[10]  Katsuji Okuda,et al.  Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. , 2006, Vaccine.

[11]  H. Blanch,et al.  Recombinant Protein Expression in High Cell Density Fed-Batch Cultures of Escherichia Coli , 1992, Bio/Technology.

[12]  E Keshavarz-Moore,et al.  Effects of growth medium selection on plasmid DNA production and initial processing steps. , 2000, Journal of biotechnology.

[13]  G W Luli,et al.  Comparison of growth, acetate production, and acetate inhibition of Escherichia coli strains in batch and fed-batch fermentations , 1990, Applied and environmental microbiology.

[14]  N. Letvin,et al.  Chemical adjuvants for plasmid DNA vaccines. , 2007, Vaccine.

[15]  J. Cabral,et al.  Anion exchange purification of plasmid DNA using expanded bed adsorption , 2000, Bioseparation.

[16]  Grzegorz Węgrzyn,et al.  Medium design for plasmid DNA production based on stoichiometric model , 2001 .

[17]  Gail Sofer,et al.  Handbook of Process Chromatography: A Guide to Optimization, Scale Up, and Validation , 1997 .

[18]  J. Rhee,et al.  Physiological constraints in increasing biomass concentration ofEscherichiacoli B in fed-batch culture , 1987, Biotechnology Letters.

[19]  Eastman,et al.  Manufacturing and quality control of plasmid-based gene expression systems. , 1998, Advanced drug delivery reviews.

[20]  Fred D. Ledley,et al.  Pharmaceutical Approach to Somatic Gene Therapy , 1996, Pharmaceutical Research.

[21]  I. Chopra,et al.  Effect of short-chain organic acids on macromolecular synthesis in Escherichia coli. , 1990, The Journal of applied bacteriology.

[22]  Detlev Riesner,et al.  High-performance liquid chromatography of high-molecular-weight nucleic acids on the macroporous ion exchanger, nucleogen , 1984 .

[23]  D. Scherman,et al.  Efficient purification of plasmid DNA for gene transfer using triple-helix affinity chromatography , 1997, Gene Therapy.

[24]  S. Lee,et al.  High cell-density culture of Escherichia coli. , 1996, Trends in biotechnology.

[25]  D. Zabriskie,et al.  Factors influencing productivity of fermentations employing recombinant microorganisms , 1986 .

[26]  Keiji Fukuda,et al.  A global pandemic influenza vaccine action plan. , 2006, Vaccine.

[27]  D L Varley,et al.  Production of plasmid DNA for human gene therapy using modified alkaline cell lysis and expanded bed anion exchange chromatography. , 1999, Bioseparation.

[28]  O Ohara,et al.  Sequence-dependent DNA separation by anion-exchange high-performance liquid chromatography. , 1996, Analytical biochemistry.

[29]  Richard C. Willson,et al.  Purification of plasmid DNA using selective precipitation by compaction agents , 1999, Nature Biotechnology.

[30]  R Schilling,et al.  A multivalent HIV-vaccine: development of a plasmid DNA for the expression of HIV envelope glycoproteins with hypervariable V3-loop domains. , 2006, Vaccine.

[31]  A Lyddiatt,et al.  Biochemical recovery and purification of gene therapy vectors. , 1998, Current opinion in biotechnology.

[32]  Lorne A. Babiuk,et al.  Approaches to Enhance the Efficacy of DNA Vaccines , 2004, Critical reviews in clinical laboratory sciences.

[33]  Kristala Jones Prather,et al.  Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification , 2003 .

[34]  Duarte M. F. Prazeres,et al.  Design of flowsheets for the recovery and purification of plasmids for gene therapy and DNA vaccination , 2004 .

[35]  C L Cooney,et al.  Purification of plasmids by triplex affinity interaction. , 1998, Nucleic acids research.

[36]  W F Swain,et al.  Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination. , 2003, Veterinary immunology and immunopathology.

[37]  C. Huber,et al.  Micropellicular stationary phases for high-performance liquid chromatography of double-stranded DNA. , 1998, Journal of chromatography. A.